Ocean Biomedical (NASDAQ: OCEA) is reporting that a broad U.S. patent has been issued to Dr. Jack A. Elias, MD, one of the company’s scientific cofounders. The patent is for bispecific antibodies targeting chitinase 3-like-1 (“CHi3L1”) and programmed cell death protein 1 (“PD-1”). The company called it “a promising new approach that has emerged from prior breakthrough discoveries that CHi3L1 is a ‘master regulator’ of tumor growth in multiple visceral cancers.” According to the announcement, the bispecific antibody is a cutting-edge immunotherapy approach that demonstrates significant potential by combining Ocean’s proprietary anti-CHi3L1 antibody with existing immune checkpoint inhibitors that target PD-1 in a bispecific-antibody format. The company reports that these bispecific antibodies “have been shown to synergistically kill tumor cells at levels dramatically exceeding the effectiveness of either the anti-CHi3L1 antibody or the anti-PD-1 antibody alone — in multiple cancer types and multiple animal models.”

According to the company, the patent has been granted for a range of cancers, including prostate, colon, rectal, ovarian, kidney, breast, glioblastoma, melanoma and lung. “This bispecific antibody pathway discovery is a monumental leap forward,” said Ocean Biomedical scientific cofounder Dr. Jack A. Elias, MD, in the press release. “By controlling CHi3L1 and concurrently targeting PD-1, you don’t just control one anti-cancer pathway, you simultaneously control many anti-cancer pathways. We believe our discoveries will advance cancer research, and eventually treatment and patient outcomes, forward.”

To view the full press release, visit https://ibn.fm/8o7vI

About Ocean Biomedical Inc.

Ocean Biomedical is a Rhode Island-based biopharma company with an innovative business model that accelerates the development and commercialization of scientifically compelling assets from research universities and medical centers. Ocean Biomedical deploys the funding and expertise to move new therapeutic candidates efficiently from the laboratory to the clinic, to the world. Ocean Biomedical is currently developing five promising discoveries that have the potential to achieve life-changing outcomes in lung cancer, brain cancer and pulmonary fibrosis, as well as the prevention and treatment of malaria. The Ocean Biomedical team is working on solving some of the world’s toughest problems, for the people who need it most. To learn more, visit www.OceanBiomedical.com.

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork